What were Glaxosmithkline Pharmaceuticals Ltd's latest quarterly results?
Glaxosmithkline Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +5.7%
- Revenue Growth YoY: +2.2%
- Operating Margin: 35.0%
Glaxosmithkline Pharmaceuticals Ltd: Stock Analysis & Fundamentals
Updated this weekGlaxosmithkline Pharmaceuticals Ltd (Pharma - MNC bulk Drugs) — fundamental analysis, earnings data, and key metrics. PE: 41.7. ROE: 45.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
Glaxosmithkline Pharmaceuticals Ltd Key Facts
Key Numbers
Current Price
₹2,367
Dividend Yield
2.41%
Market Cap
40.1K Cr
Valuation
N/AOther Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Glaxosmithkline Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Glaxosmithkline Pharmaceuticals Ltd's current PE ratio?
Glaxosmithkline Pharmaceuticals Ltd's current PE ratio is 41.7x.
- Current PE: 41.7x
- Market Cap: 40.1K Cr
- Dividend Yield: 2.41%
What is Glaxosmithkline Pharmaceuticals Ltd's price-to-book ratio?
Glaxosmithkline Pharmaceuticals Ltd's price-to-book ratio is 17.7x.
- Price-to-Book (P/B): 17.7x
- Book Value per Share: ₹134
- Current Price: ₹2367
Is Glaxosmithkline Pharmaceuticals Ltd a fundamentally strong company?
Glaxosmithkline Pharmaceuticals Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 61.0%
Is Glaxosmithkline Pharmaceuticals Ltd debt free?
Glaxosmithkline Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹33 Cr
What is Glaxosmithkline Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Glaxosmithkline Pharmaceuticals Ltd's return ratios over recent years
- FY2024: ROCE 51.0%
- FY2025: ROCE 63.0%
- FY2026: ROCE 61.0%
Is Glaxosmithkline Pharmaceuticals Ltd's cash flow positive?
Glaxosmithkline Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹903 Cr
- Free Cash Flow (FCF): ₹1,000 Cr
- CFO/PAT Ratio: 87% (strong cash conversion)
What is Glaxosmithkline Pharmaceuticals Ltd's dividend yield?
Glaxosmithkline Pharmaceuticals Ltd's current dividend yield is 2.41%.
- Dividend Yield: 2.41%
- Current Price: ₹2367
Who holds Glaxosmithkline Pharmaceuticals Ltd shares — promoters, FII, DII?
Glaxosmithkline Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 75.0%
- FII (Foreign): 4.6%
- DII (Domestic): 7.7%
- Public: 12.7%
Is promoter holding increasing or decreasing in Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 75.0% (Mar 2026)
- Previous Quarter: 75.0% (Dec 2025)
- Change: 0.00% (stable)
Is Glaxosmithkline Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Glaxosmithkline Pharmaceuticals Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Glaxosmithkline Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Glaxosmithkline Pharmaceuticals Ltd may be worth studying
- Cash flow is positive — CFO ₹903 Cr
What is the investment thesis for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd investment thesis summary:
What is the future outlook for Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.